AMENDMENTS TO THE SPECIFICATION

A. Brief Description of the Drawings

Please replace the paragraph at page 11, line 4-6 of the specification with the following rewritten paragraph:

Figure 4 is a plot of the percent drug released versus time from the coated pellets described in Example 2 which exemplifies ~~the immediate release component and~~ the delayed release components of the present invention.

Please replace the paragraph at page 11, lines 7-9 of the specification with the following rewritten paragraph:

Figure 5 is a plot of the percent drug released versus time from the coated pellets of Example 3 which exemplifies ~~the immediate release component and~~ the delayed release components of the present invention.

Please replace the paragraph at page 11, lines 10-12 of the specification with the following rewritten paragraph:

Figure 6 illustrates the drug release profile of coated pellets described in Example 4 which exemplifies ~~the immediate release component and~~ the delayed release components of the present invention.

B. Example 2: MASL Pellets, Fluid Bed Processor and 20 Microns

Please replace the paragraph at page 18, lines 2-13 of the specification with the following rewritten paragraph:

The following formulation was used to coat the mixed amphetamine salts loaded (MASL) pellets from Example 1 with the EUDRAGIT® L 30D-55 (Rohm Pharma, Germany) coating dispersion. 2 kg of MASL pellets were loaded into a fluid bed processor with a reduced Wurster column equipped with a precision coater ~~(MP 2/3, Niro Inc.)~~ (see Example 3 and Example 4). The coating dispersion was prepared by dispersing Triethyl citrate, Talc and EUDRAGIT® L 30D-55 into water and mixing for at least 30 minutes. Under suitable fluidization conditions, the coating dispersion was sprayed onto the fluidized MASL pellets. The spraying was continued until the targeted coating level was achieved [[(20μ)]]. The coated pellets were dried at 30-35 °C for 5 minutes before stopping the process. The enteric coated [[PPA]] MASL pellets were tested at different pH buffers by a USP paddle method. The drug content was analyzed using HPLC. The results showed that the enteric coating delayed the drug release from the coated pellets until after exposure to pH 6 or higher (see Table 2 below). (Reference # AR98I25-4)

C. **Table 2**

Please replace the table beginning at page 18, line 14 of the specification with the following rewritten table:

TABLE 2

Ingredients	Amount (%)
MASL pellets	[[40.00]] 70.00
EUDRAGIT® L 30D-55	24.88
Triethyl citrate	2.52
Talc	2.60
Water	*

D. Table 3

Please replace the table beginning at page 19, line 7 of the specification with the following rewritten table:

TABLE 3

Ingredients	Amount (%)
MASL pellets	[[70.00]]
Eudragit® 4110D	[[26.24]]
Triethyl citrate	[[0.76]]
Talc	[[3.00]]
Water	*